Strengthening these findings is a meta‐analysis of 1782 MDS patients across six studies that detected IDH mutations in 111 patients (6.2%), which predicted poor prognosis, with inferior OS (HR 1.62; CI, 1.27–2.09) and LFS (HR 2.21; CI, 1.48–3.30). Here, IDH2 is linked to myelodysplastic syndrome.